Acinetobacter baumannii 2002-2008: Increase of carbapenem-associated multiclass resistance in the United States

Microbial Drug Resistance

Volumn 16, Issue 3, 2010, Pages 209-215

  Mera, Robertino M ^a   Miller, Linda A ^a   Amrine Madsen, Heather ^a   Sahm, Daniel F ^b  

^a GLAXOSMITHKLINE   (United States)

^b Eurofins Medinet Inc   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE DERIVATIVE; BETA LACTAM ANTIBIOTIC; BETA LACTAMASE INHIBITOR; CARBAPENEM DERIVATIVE; CEFEPIME; CEFTAZIDIME; CEPHALOSPORIN DERIVATIVE; CIPROFLOXACIN; GENTAMICIN; IMIPENEM; LEVOFLOXACIN; MEROPENEM; PIPERACILLIN PLUS TAZOBACTAM; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TIMENTIN; TOBRAMYCIN;

ACINETOBACTER BAUMANNII; ADULT; AGE DISTRIBUTION; AGED; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIDRUG RESISTANCE; NONHUMAN; PRIORITY JOURNAL; RISK FACTOR; UNITED STATES;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTIONS; ANTI-BACTERIAL AGENTS; CARBAPENEMS; DATABASES, FACTUAL; DRUG RESISTANCE, MULTIPLE, BACTERIAL; HOSPITALIZATION; HUMANS; INTERNET; LOGISTIC MODELS; MICROBIAL SENSITIVITY TESTS; POPULATION SURVEILLANCE; PREVALENCE; RISK FACTORS; UNITED STATES;

ACINETOBACTER BAUMANNII;

EID: 77956569443     PISSN: 10766294     EISSN: None     Source Type: Journal    
DOI: 10.1089/mdr.2010.0052     Document Type: Article

References (29)

1. Chen, H.P., T.L. Chen, C.H. Lai, C.P. Fung, W.W. Wong, K.W. Yu, and C.Y. Liu. 2005. Predictors of mortality in Acinetobacter baumannii bacteremia. J. Microbiol. Immunol. Infect. 38:127-136.
2. Choi, J.Y., Y.S. Park, C.O. Kim, H.J. Yoon, S.Y. Shin, Y.A. Kim, Y.G. Song, D. Yong, K. Lee, and J.M. Kim. 2005. Mortality risk factors of Acinetobacter baumannii bacteraemia. Intern. Med. J. 35:599-603.
3. Cisneros, J.M., M.J. Reyes, J. Pachón, B. Becerril, F.J. Caballero, J.L. García-Garmendía, C. Ortiz, and A.R. Cobacho. 1996. Bacteremia due to Acinetobacter baumannii: epidemiology, clinical findings, and prognostic features. Clin. Infect. Dis. 22:1026-1032.
4. Cisneros, J.M., and J. Rodriguez-Baño. 2002. Nosocomial bac-teremia due to Acinetobacter baumannii: epidemiology, clinical features and treatment. Clin. Microbiol. Infect. 8:687-693
5. [CLSI] Clinical and Laboratory Standards Institute. 2008. Performance standards for antimicrobial susceptibility testing; eighteenth informational supplement. CLSI document M100-S18, Wayne, PA.
6. Crowe, M., P. Ispahani, H. Humphreys, T. Kelley, and R. Winter. 1998. Bacteraemia in the adult intensive care unit of a teaching hospital in Nottingham, UK, 1985-96. Eur. J. Clin. Microbiol. Infect. Dis. 17:377-384.
7. Falagas, M.E., P. Kopterides, and I.I. Siempos. 2006. Attributable mortality of Acinetobacter baumannii infection among critically ill patients. Clin. Infect. Dis. 43:389.
8. Ferrara, A.M. 2006. Potentially multidrug-resistant non-fermentative gram-negative pathogens causing nosocomial pneumonia. Int. J. Antimicrob. Agents. 27:183-195.
9. Hoffman M.S., M.R. Eber, and R. Laxminarayan. 2010. Increasing resistance of acinetobacter species to imipenem in United States Hospitals, 1999-2006. Infect Control Hosp. Epidemiol. 31:196-197.
10. Gales, A.C., R.N. Jones, K.R. Forward, J. Liñ ares, H.S. Sader, and J. Verhoef. 2001. Emerging importance of mul-tidrug-resistant Acinetobacter species and Stenotrophomonas maltophilia as pathogens in seriously ill patients: geographic patterns, epidemiological features, and trends in the SENTRY Antimicrobial Surveillance Program (1997-1999). Clin. Infect. Dis. 32:S104-S113.
11. Garcia-Garmendia, J.L., C. Ortiz-Leyba, J. Garnacho-Montero, F.J. Jiménez-Jiménez, C. Pérez-Paredes, A.E. Barrero-Almodóvar, and M. Gili-Miner. 2001. Risk factors for Acinetobacter baumannii nosocomial bacteraemia in critically ill patients: a cohort study. Clin. Infect. Dis. 33:939-946.
12. Gaynes, R., J.R. Edwards, and the National Nosocomial Infections Surveillance System. 2005. Overview of noso-comial infections caused by gram-negative bacilli. Clin. Infect. Dis. 41:848-854.
13. Gkrania-Klotsas, E., and R.C. Hershow. 2006. Colonization or infection with multidrug resistant Acinetobacter baumannii may be an independent risk factor for increased mortality. Clin. Infect. Dis. 43:1224-1225.
14. Joly-Guillou, M.L. Clinical impact and pathogenicity of Acinetobacter. 2005. Clin. Microbiol. Infect. 11:868-873.
15. Kwon, K.T., W.S. Oh, J.H. Song, H.H. Chang, S.I. Jung, S.W. Kim, S.Y. Ryu, S.T. Heo, D.S. Jung, J.Y. Rhee, S.Y. Shin, K.S. Ko, K.R. Peck, and N.Y. Lee. 2007. Impact of imipenem resistance on mortality in patients with Acineto-bacter bacteraemia. J. Antimicrob. Chemother. 59:525-530.
16. Landman, D., S. Bratu, S. Kochar, M. Panwar, M. Trehan, M. Doymaz, and J. Quale. 2007. Evolution of antimicrobial resistance among Pseudomonas aeruginosa, Acinetobacter baumannii and Klebsiella penumoniae in Brooklyn, NY. J. An-timicrob. Chemother. 60:78-82.
17. Lautenbach, E., M. Synnestvedt, M.G. Weiner, W.B. Bilker, L. Vo, J. Schein, and M. Kim. Epidemiology and impact of imipenem resistance in Acinetobacter baumannii. 2009. Infect. Control Hosp. Epidemiol. 30:1186-1192.
18. Lee, C.M., H.K. Lim, C.P. Liu, and H.K. Tseng. 2005. Treatment of pan-drug resistant Acinetobacter baumannii. Scand. J. Infect. Dis. 37:195-199.
19. Lee, N., H. Lee, and N. Ko. 2005. Impact of multidrug antimicrobial resistance on the health outcomes and economic burden in cases with Acinetobacter baumannii bacteremia. In Abstracts of the 45th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, DC, 2005. Abstract K1303, p. 336. American Society for Microbiology, Washington, DC.
20. McDonald, L.C., S.N. Banerjee, and W.R. Jarvis. 1999. Seasonal variation of Acinetobacter infections: 1987-1996. Clin. Infect. Dis. 29:1133-1137.
21. Peleg, A.Y., H. Seifert, and D.L. Paterson. 2008. Acineto-bacter baumannii: emergence of a successful pathogen. Clin. Microbiol. Rev. 21:538-582.
22. Poirel, L., T. Naas, and P. Nordmann. 2010. Diversity, epidemiology, and genetics of class D b-lactamases. Anti-microb. Agents Chemother. 54:24-38.
23. Sahm, D.F., M.K. Marsilio, and G. Piazza. 1999. Antimicrobial resistance in key bloodstream bacterial isolates: electronic surveillance with The Surveillance Network Database-USA. Clin. Infect. Dis. 29:259-263.
24. Seifert, H., A. Strate, and G. Pulverer. 1995. Nosocomial bacteremia due to Acinetobacter baumannii. Clinical features, epidemiology, and predictors of mortality. Medicine 74: 340-349.
25. Styers, D., D.J. Sheehan, P. Hogan, and D.F. Sahm. 2006. Laboratory-based surveillance of current antimicrobial resistance patterns and trends among Staphylococcus aureus: 2005 status in the United States. Ann. Clin. Microbiol. An-timicrob. 5:2.
26. Sunenshine, R.H., M.O. Wright, L.L. Maragakis, A.D. Harris, X. Song, J. Hebden, S.E. Cosgrove, A. Anderson, J. Carnell, D.B. Jernigan, D.G. Kleinbaum, T.M.Perl, H.C. Standiford, and A. Srinivasan. 2007. Multidrug-resistant Acinetobacter infection mortality rate and length of hospi-talization. Emerg. Infect. Dis. 13:97-103.
27. Tilley, P.A., and F.J. Roberts. 1994. Bacteremia with Acine-tobacter species: risk factors and prognosis in different clinical settings. Clin. Infect. Dis. 18:896-900.
28. Wisplinghoff, H., T. Bischoff, S.M. Tallent, H. Seifert, R.P. Wenzel, and M.B. Edmond. 2004. Nosocomial bloodstream infections in US hospitals: analysis of 24 179 cases from a prospective nationwide surveillance study. Clin. Infect. Dis. 39:309-317.
29. Zarrilli, R., Giannouli M., Tomasone F., Triassi M., and A. Tsakris. 2009. Carbapenem resistance in Acinetobacter bau-mannii: the molecular epidemic features of an emerging problem in health care facilities. J. Infect. Dev. Ctries. 3:335-341.